Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation

This study has been completed.
Information provided by (Responsible Party):
Yosanan Yospaiboon, Khon Kaen University Identifier:
First received: July 11, 2005
Last updated: March 7, 2012
Last verified: March 2012
The purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination.

Condition Intervention Phase
Eye Diseases
Drug: 1% tropicamide and 10% phenylephrine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation

Resource links provided by NLM:

Further study details as provided by Khon Kaen University:

Primary Outcome Measures:
  • horizontal pupil diameter [ Time Frame: 30 min ]

Secondary Outcome Measures:
  • systolic blood pressure [ Time Frame: 30 min ]
  • diastolic blood pressure [ Time Frame: 30 min ]
  • heart rate [ Time Frame: 30 min ]
  • adverse drug reaction [ Time Frame: 30 min ]

Enrollment: 80
Study Start Date: December 2004
Study Completion Date: June 2005
Arms Assigned Interventions
Active Comparator: A
single dose vs three doses of 1%tropicamide and 10%phenylephrine
Drug: 1% tropicamide and 10% phenylephrine
single dose vs three doses of 1%tropicamide and 10%phenylephrine

Detailed Description:
To the best of the authors' knowledge, there have been no clinical trials using an appropriate regimen for pupillary dilation up until now. Therefore, the authors were interested to find out the most appropriate regimen for complete ocular examination, based on the finding that a pupil diameter of 6 mm or greater is adequate for indirect ophthalmoscopy. The authors hypothesize that a single dose of 1% tropicamide and 10% phenylephrine is adequate to complete the job and are conducting this prospective randomized clinical controlled trial to prove the hypothesis.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • aged between 20 and 80 years old
  • dark iris
  • require binocular indirect ophthalmoscopy for complete ocular examination
  • signed written consent forms

Exclusion Criteria:

  • history of ocular trauma
  • history of intraocular surgery
  • history of laser treatment
  • previous eye drop instillation that may affect pupillary dilation
  • ocular diseases that may affect pupil size such as Horner's syndrome, Adies' pupil, glaucoma and uveitis
  • history of diabetes mellitus, severe hypertension and cardiovascular diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00120432

Srinagarind Hospital
Khon Kaen, Thailand, 40002
Sponsors and Collaborators
Khon Kaen University
Principal Investigator: Yosanan Yospaiboon, M.D. Faculty of Medicine, Khon Kaen University
  More Information

Responsible Party: Yosanan Yospaiboon, Professor, Khon Kaen University Identifier: NCT00120432     History of Changes
Other Study ID Numbers: HE461104
Study First Received: July 11, 2005
Last Updated: March 7, 2012

Keywords provided by Khon Kaen University:
single dose
mydriatic drug
pupillary dilation

Additional relevant MeSH terms:
Eye Diseases
Dilatation, Pathologic
Pathological Conditions, Anatomical
Pupil Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cardiotonic Agents
Vasoconstrictor Agents
Nasal Decongestants
Respiratory System Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Protective Agents processed this record on May 22, 2017